The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
The Duration of Action of Zoledronate study
Scientific title
A three year randomised, double-blind, placebo-controlled trial to determine the duration of effect of zoledronate on bone turnover markers and on bone density in post menopausal women with osteopenia.
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Post menopausal Osteopenia 366 0
Condition category
Condition code
Reproductive Health and Childbirth 428 428 0 0
Menstruation and menopause
Musculoskeletal 429 429 0 0
Other muscular and skeletal disorders

Study type
Description of intervention(s) / exposure
One infusion of 5mg intravenous zoledronate.
Intervention code [1] 323 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 492 0
The time to normalisation of bone turnover markers in the zoledronate treated group where normalisation is defined as when the mean of a bone turnover marker in the zoledronate treated group lies within 20% of the mean value of that marker in the placebo treated group.
Timepoint [1] 492 0
Secondary outcome [1] 1056 0
The difference between the change in bone turnover markers.
Timepoint [1] 1056 0
Over 3 years in the zoledronate-treated group compared to the change in the control group.
Secondary outcome [2] 1057 0
The difference between the change in spine and hip bone density.
Timepoint [2] 1057 0
Over 3 years in the zoledronate-treated group compared to the change in the control group.

Key inclusion criteria
Postmenopausal 5 yrs or more, bone density T score between -1.0 and -2.0 at lumbar spine or total hip.
Minimum age
18 Years
Maximum age
Not stated
Can healthy volunteers participate?
Key exclusion criteria
Renal impairment (serum creatinine >0.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP > 2x normal limit, primary hyperparathyroidism, previous fragility fracture of the hip or spine. Use of oral glucocorticoid drugs equivalent to an average dose of prednisone 2.5 mg/day in the preceding 12 months, current or past use of bisphosphonate therapy, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism.

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Medication was prepared by a doctor not involved with study participants. The medication was then administered by a study nurse who was unaware of the contents. Thus all study personnel with patient contact were blinded.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random numbers in variable blocks.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 158 0
New Zealand
State/province [1] 158 0

Funding & Sponsors
Funding source category [1] 481 0
Government body
Name [1] 481 0
Health Research Council of New Zealand
Address [1] 481 0
Country [1] 481 0
New Zealand
Primary sponsor type
Professor I Reid
Secondary sponsor category [1] 388 0
Name [1] 388 0
University of Auckland Bone Research Group
Address [1] 388 0
Country [1] 388 0
New Zealand

Ethics approval
Ethics application status
Ethics committee name [1] 1460 0
Auckland University
Ethics committee address [1] 1460 0
Ethics committee country [1] 1460 0
New Zealand
Date submitted for ethics approval [1] 1460 0
Approval date [1] 1460 0
Ethics approval number [1] 1460 0

Brief summary
This is a 3 year study designed to determine the duration of action of a single dose of intravenous zoledronate.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35483 0
Address 35483 0
Country 35483 0
Phone 35483 0
Fax 35483 0
Email 35483 0
Contact person for public queries
Name 9512 0
Diana Wattie
Address 9512 0
Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020
Country 9512 0
New Zealand
Phone 9512 0
+64 9 3078970
Fax 9512 0
+64 9 3737677
Email 9512 0
Contact person for scientific queries
Name 440 0
Professor Reid
Address 440 0
Bone Research Group
Department of Medicine
Auckland University
Private Bag 92 019
Auckland 1020
Country 440 0
New Zealand
Phone 440 0
+64 9 3737599
Fax 440 0
+64 9 3737677
Email 440 0

No data has been provided for results reporting
Summary results
Not applicable